@entity1175 and hypoplastic uterus associated with @entity4089 : successful treatment with XXXX .

@entity1 @entity4089 @entity7831 @entity2847 @entity1175 @entity4090 @entity4611 @entity2588
A 15-year-old @entity1 referred because of primary @entity2588 was found to have a hypoplastic uterus and persistent @entity4089 (72-110 ng/ml). The gonadotrophin-dependent pubertal signs, i.e. breast and vulvar development, were significantly retarded (Tanner stage 2-3) while sexual hair was well developed; bone age was 13 years. The endocrinological evaluation revealed gonadotrophin secretion (LH-basal: 0.85-1.25; peak after LH-RH: 10.4 mIU/ml; FSH-basal: 1.63-2.5; peak: 8.2 mIU/ml) and E2 levels (26-68 pg/ml) which were appropriate for Tanner stage 3. The high basal levels of @entity4090 were nonresponsive to either stimulatory (TRH) or inhibitory ( @entity7831 ) agents. CT scan of the brain suggested the presence of a @entity4611 . Following therapy with @entity2847 (2.5 mg/day) plasma @entity4090 levels dropped to normal (5-6.8 ng/ml) with an accompanying catch-up of pubertal development and linear growth and a marked increase in size of the uterus as documented by repeated ultrasonographic examinations. Menarche occurred 5 months after initiation of therapy, followed by regular menses thereafter. Repeated CT scan of the brain showed a decrease in the density and size of the still persisting lesion. This @entity1 demonstrates that @entity4089 can cause delayed @entity1175 with a particular inhibitory effect on uterine growth and development.
